---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-22-259591"
form_type: "8-K"
ticker: "AGIO"
cik: "0001439222"
company_name: "AGIOS PHARMACEUTICALS, INC."
filed_at: "2022-10-07T23:59:59+00:00"
generated_at: "2026-06-23T04:40:38.902367+00:00"
event_type: "other"
sentiment: "neutral"
materiality_score: 0.4
calibrated_materiality_score: 0.4
confidence: "high"
source: SEC EDGAR
---

# Agios amends severance plan; expands C-Level definition, alters equity vesting rules

## Summary
- C-Level Employee definition expanded to include any job title above Senior Vice President.
- New-Hire Equity Awards granted after October 6, 2022 will have accelerated vesting on non-Change-of-Control termination or death/disability.
- Change-of-Control Termination now triggers full vesting of service-based equity awards; performance awards per original plan terms.
- Post-Change-of-Control amendment/termination restriction period increased from 12 to 18 months.

## SEC filing metadata
- accession: 0001193125-22-259591
- form_type: 8-K
- ticker: AGIO
- cik: 0001439222
- company_name: AGIOS PHARMACEUTICALS, INC.
- filed_at: 2022-10-07T23:59:59+00:00
- event_type: other
- sentiment: neutral
- materiality_score: 0.4
- calibrated_materiality_score: 0.4
- confidence: high
- sec_items: 5.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1439222/000119312522259591/0001193125-22-259591-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1439222/000119312522259591/d363139d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-22-259591
- JSON: https://secwatch.observer/filing/0001193125-22-259591.json
- Plain text: https://secwatch.observer/filing/0001193125-22-259591.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.